Growth in turner syndrome

E. Kirk Neely, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although the pathogenesis of growth failure in Turner syndrome remains uncertain, recent clinical trials with human growth hormone (hGH), androgens, and estrogens permit us to make several observations regarding effective growth-promoting therapy. Treatment with hGH alone provides a modest, but significant, increase in growth velocity for Turner patients, an effect that can be best appreciated when results are compared with the natural history of untreated Turner girls. Growth hormone, alone and in combination with oxandrolone, also appears to have a favorable effect upon final height. In on-going studies using recombinant hGH, over 75% of subjects have already exceeded their projected adult height, and an adult height over 150 cm appears to be a reasonable goal for most girls with Turner syndrome. Although the addition of low-dose oxandrolone to hGH further increases growth velocity, it is still too early to determine whether hGH alone or combination therapy will result in the better final height. Therefore, the role for oxandrolone in routine management of Turner syndrome remains to be determined. Estrogen does not appear to have a role in growth therapy, but the growth response to hGH theoretically allows for earlier addition of low-dose estrogen for feminization. Lastly, we recommend that hGH therapy begin as soon as significant growth deceleration occurs: not only is the beneficial effect on final adult height potentially greater, but girls with Turner syndrome can also receive the psychological benefit of remaining close to the normal growth curve during childhood.

Original languageEnglish (US)
Pages (from-to)313-322
Number of pages10
JournalEndocrinologist
Volume1
Issue number4
StatePublished - 1991
Externally publishedYes

Fingerprint

Turner Syndrome
Human Growth Hormone
Oxandrolone
Growth
Estrogens
Growth Hormone
Feminization
Therapeutics
Deceleration
Natural History
Androgens
Clinical Trials
Psychology

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Neely, E. K., & Rosenfeld, R. R. (1991). Growth in turner syndrome. Endocrinologist, 1(4), 313-322.

Growth in turner syndrome. / Neely, E. Kirk; Rosenfeld, Ronald (Ron).

In: Endocrinologist, Vol. 1, No. 4, 1991, p. 313-322.

Research output: Contribution to journalArticle

Neely, EK & Rosenfeld, RR 1991, 'Growth in turner syndrome', Endocrinologist, vol. 1, no. 4, pp. 313-322.
Neely EK, Rosenfeld RR. Growth in turner syndrome. Endocrinologist. 1991;1(4):313-322.
Neely, E. Kirk ; Rosenfeld, Ronald (Ron). / Growth in turner syndrome. In: Endocrinologist. 1991 ; Vol. 1, No. 4. pp. 313-322.
@article{294a6b1f8d884b02923971c7604d6ab2,
title = "Growth in turner syndrome",
abstract = "Although the pathogenesis of growth failure in Turner syndrome remains uncertain, recent clinical trials with human growth hormone (hGH), androgens, and estrogens permit us to make several observations regarding effective growth-promoting therapy. Treatment with hGH alone provides a modest, but significant, increase in growth velocity for Turner patients, an effect that can be best appreciated when results are compared with the natural history of untreated Turner girls. Growth hormone, alone and in combination with oxandrolone, also appears to have a favorable effect upon final height. In on-going studies using recombinant hGH, over 75{\%} of subjects have already exceeded their projected adult height, and an adult height over 150 cm appears to be a reasonable goal for most girls with Turner syndrome. Although the addition of low-dose oxandrolone to hGH further increases growth velocity, it is still too early to determine whether hGH alone or combination therapy will result in the better final height. Therefore, the role for oxandrolone in routine management of Turner syndrome remains to be determined. Estrogen does not appear to have a role in growth therapy, but the growth response to hGH theoretically allows for earlier addition of low-dose estrogen for feminization. Lastly, we recommend that hGH therapy begin as soon as significant growth deceleration occurs: not only is the beneficial effect on final adult height potentially greater, but girls with Turner syndrome can also receive the psychological benefit of remaining close to the normal growth curve during childhood.",
author = "Neely, {E. Kirk} and Rosenfeld, {Ronald (Ron)}",
year = "1991",
language = "English (US)",
volume = "1",
pages = "313--322",
journal = "Endocrinologist",
issn = "1051-2144",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Growth in turner syndrome

AU - Neely, E. Kirk

AU - Rosenfeld, Ronald (Ron)

PY - 1991

Y1 - 1991

N2 - Although the pathogenesis of growth failure in Turner syndrome remains uncertain, recent clinical trials with human growth hormone (hGH), androgens, and estrogens permit us to make several observations regarding effective growth-promoting therapy. Treatment with hGH alone provides a modest, but significant, increase in growth velocity for Turner patients, an effect that can be best appreciated when results are compared with the natural history of untreated Turner girls. Growth hormone, alone and in combination with oxandrolone, also appears to have a favorable effect upon final height. In on-going studies using recombinant hGH, over 75% of subjects have already exceeded their projected adult height, and an adult height over 150 cm appears to be a reasonable goal for most girls with Turner syndrome. Although the addition of low-dose oxandrolone to hGH further increases growth velocity, it is still too early to determine whether hGH alone or combination therapy will result in the better final height. Therefore, the role for oxandrolone in routine management of Turner syndrome remains to be determined. Estrogen does not appear to have a role in growth therapy, but the growth response to hGH theoretically allows for earlier addition of low-dose estrogen for feminization. Lastly, we recommend that hGH therapy begin as soon as significant growth deceleration occurs: not only is the beneficial effect on final adult height potentially greater, but girls with Turner syndrome can also receive the psychological benefit of remaining close to the normal growth curve during childhood.

AB - Although the pathogenesis of growth failure in Turner syndrome remains uncertain, recent clinical trials with human growth hormone (hGH), androgens, and estrogens permit us to make several observations regarding effective growth-promoting therapy. Treatment with hGH alone provides a modest, but significant, increase in growth velocity for Turner patients, an effect that can be best appreciated when results are compared with the natural history of untreated Turner girls. Growth hormone, alone and in combination with oxandrolone, also appears to have a favorable effect upon final height. In on-going studies using recombinant hGH, over 75% of subjects have already exceeded their projected adult height, and an adult height over 150 cm appears to be a reasonable goal for most girls with Turner syndrome. Although the addition of low-dose oxandrolone to hGH further increases growth velocity, it is still too early to determine whether hGH alone or combination therapy will result in the better final height. Therefore, the role for oxandrolone in routine management of Turner syndrome remains to be determined. Estrogen does not appear to have a role in growth therapy, but the growth response to hGH theoretically allows for earlier addition of low-dose estrogen for feminization. Lastly, we recommend that hGH therapy begin as soon as significant growth deceleration occurs: not only is the beneficial effect on final adult height potentially greater, but girls with Turner syndrome can also receive the psychological benefit of remaining close to the normal growth curve during childhood.

UR - http://www.scopus.com/inward/record.url?scp=84930097012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930097012&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84930097012

VL - 1

SP - 313

EP - 322

JO - Endocrinologist

JF - Endocrinologist

SN - 1051-2144

IS - 4

ER -